Tombstone Megapharm.pdf
16. October 2008
Medicis Capital served as the key financial advisor to Megapharm and its shareholders
www.allianceboots.com
Alliance Boots acquires megapharm in Germany
Alliance Boots has today acquired a 90% stake in megapharm GmbH, a specialised German distributor of oncology products. The acquisition, which has recently been approved by EU competition regulators, will enable Alliance Boots to enhance its position in the specialty drugs sector.
Based in Sankt Augustin, near Bonn, megapharm provides a range of specialised wholesaling and logistics services for oncology products. It is the only wholesaler in Germany to supply the full range of oncology drugs. The revenue for megapharm for the year ended 31 March 2008 was approximately £235 million. Within Alliance Boots, the new business will become part of the Pharmaceutical Wholesale Division which is led by Ornella Barra, Board Member and Wholesale & Commercial Affairs Director of Alliance Boots.
A 10% stake in megapharm will be held by Dr. Matthias Ackermann, its current Chief Executive, who will continue to lead the business.
Stefano Pessina, Executive Chairman, Alliance Boots, commented: "This significant acquisition in the highly attractive oncology segment of the market will further extend the range of specialist added-value services we offer our manufacturer and pharmacist customers and is in line with our strategy of broadening our wholesaling services beyond traditional pharmaceutical wholesaling."
ENDS
For further information, please contact:
Yves Romestan / Zoe Farthing, Communications
Tel: +44 (0) 1932 871569
James Murgatroyd/Kirsty Flockhart, Finsbury
Tel: +44 (0) 20 7251 3801
16/10/2008
http://www.apotheke-adhoc.de/
ONKOLOGIE
Alliance Boots kauft in Deutschland
Berlin - Der britische Pharmahandelskonzern Alliance Boots steigt als Mehrheitseigner beim deutschen Spezialgroßhändler Megapharm ein. Die EU-Kommission genehmigte in dieser Woche den bereits Anfang September beantragten Zusammenschluss. Für einen unbekannten Preis gehen rund 90 Prozent der Anteil an Europas drittgrößten Pharmahändler. Alliance Boots ist abgesehen von seiner Beteiligung an der Anzag sowie einigen kleineren Investments bislang nicht in Deutschland vertreten.
Megapharm hat sich auf den Vertrieb von onkologischen Produkten spezialisiert und beliefert eigenen Angaben zufolge rund 400 Apotheken und arbeitet mit einer Vielzahl der 350 niedergelassene Hämatoonkologen zusammen. Laut Geschäftsführer Dr. Matthias Ackermann ist das Unternehmen der einzige vollsortierte Großhändler im Bereich der Onkologie; fast die Hälfte der angebotenen Produkte ist nicht im klassischen Pharmagroßhandel verfügbar.
Im vergangenen Jahr erwirtschaftete Megapharm knapp 290 Millionen Euro, fast ein Drittel mehr als im Vorjahr. Der Rohertrag lag mit 9,6 Millionen Euro 6 Prozent über Vorjahresniveau. Nur noch ein Drittel der rund 100 Angestellten sind laut Ackermann in der Logistik tätig; Megapharm engagiert sich außerdem in der Aufarbeitung medizinischer Daten, Verhandlungen zur integrierten Versorgung sowie in der Forschung.
Dem Firmengründer zufolge will Alliance Boots Megapharm in diesen Bereichen weiter ausbauen. Eine Ausdehnung des Großhandelsgeschäfts auf andere Indikationen sei dagegen nicht geplant. Aufgrund des inhaltlichen Ansatzes habe der Konzern aus Großbritannien auch den Zuschlag erhalten. Megapharm hatte einen neuen Partner gesucht, nachdem zwei der bisherigen Eigentümer aussteigen wollten: Bislang hatten neben Ackermann Wilfried Mohr, Chef des onkologischen Generikahersteller Medac, sowie Ferdinand Bach, Chef des Forschungsunternehmens Oncoscience, Anteile an Megapharm gehalten.
Patrick Hollstein, Mittwoch, 15. Oktober 2008, 18:24 Uhr
http://www.retail-week.com/
Alliance Boots buys German distributor Megapharm
Alliance Boots has bought a 90 per cent stake in German specialist drugs distributor Megapharm.
The acquisition of Megapharm, which distributes oncology products, has been approved by European Union competition regulators and will extend Alliance Boots' reach in the specialty drugs sector.
The move is the latest in a string of acquisitions by Alliance Boots, which is focusing on building its international presence.
Megapharm will become part of the pharmaceutical wholesale division of Alliance Boots, led by board member and wholesale and commercial affairs director Ornella Barra.
Megapharm chief executive Dr Matthias Ackermann will retain a 10 per cent stake and continue to head the business. Revenue at Megapharm in the year to March 31 was about £235 million.
Alliance Boots executive chairman Stefano Pessina said: "This significant acquisition in the highly attractive oncology segment of the market will further extend the range of specialist added-value services we offer our manufacturer and pharmacist customers and is in line with our strategy of broadening our wholesaling services beyond traditional pharmaceutical wholesaling."
To comment on this story, post a response below or e-mail Retail Week.
Business Brief: Alliance Boots PLC
125 Wörter
17 Oktober 2008
The Wall Street Journal Europe
A7
Englisch
(Copyright (c) 2008, Dow Jones & Company, Inc.)
U.K.-based Alliance Boots PLC, owner of the Boots health and beauty retail chain, said it acquired a 90% stake in Megapharm GmbH, a specialized German distributor of oncology products. The company said the acquisition will help it enhance its position in the specialty drugs sector. Based in Sankt Augustin, near Bonn, Megapharm is the only wholesaler in Germany to supply a full range of oncology drugs. Alliance Boots said Megapharm generated revenue of around GBP 235 million ($404.6 million) in its fiscal year ended March 31. The remaining 10% stake in Megapharm will be held by Matthias Ackermann, its current chief executive, who will continue to lead the business.
License this article from Dow Jones Reprint Service
Dokument WSJE000020081017e4ah0002i
Alliance Boots Buys 90% Stake In Megapharm
232 Wörter
16 Oktober 2008
15:45
Dow Jones International News
Englisch
(c) 2008 Dow Jones & Company, Inc.
LONDON (Dow Jones)--U.K. pharmacy-led health and beauty firm Alliance Boots said Thursday it has acquired a 90% stake in Megapharm GmbH, a specialized German distributor of oncology products.
The company said the acquisition, which earlier this week was approved by the European Commission, will enable it to "enhance its position in the specialty drugs sector."
Based in Sankt Augustin, near Bonn, Megapharm provides a range of specialized wholesaling and logistics services for oncology products. It is the only wholesaler in Germany to supply the full range of oncology drugs. The revenue for Megapharm for the year ended March 31 was approximately GBP235 million, according to Alliance Boots.
Within Alliance Boots, the new business will become part of the Pharmaceutical Wholesale division, which is led by Ornella Barra.
The remaining 10% stake in Megapharm will be held by Matthias Ackermann, its current chief executive, who will continue to lead the business.
Alliance Boots Executive Chairman Stefano Pessina said: "This significant acquisition in the highly attractive oncology segment of the market will further extend the range of specialist added-value services we offer our manufacturer and pharmacist customers and is in line with our strategy of broadening our wholesaling services beyond traditional pharmaceutical wholesaling."
-By Lilly Vitorovich, Dow Jones Newswires; 44-0-207 842 9290; lilly.vitorovich@dowjones.com [ 16-10-08 1503GMT ]
Dokument DJI0000020081016e4ag000qa
Agenda
Alliance Boots entert deutschen Pharmahandel
FTD
98 Wörter
16 Oktober 2008
Financial Times Deutschland
29
Deutsch
(c) 2008 - All rights reserved. Copyright Financial Times Deutschland, Hamburg.
Der britische Pharmagroßhändler und Apothekenkettenbetreiber Alliance Boots steigt in den deutschen Markt ein. Mit der Zustimmung der Europäischen Kommission übernimmt der britische Konzern den auf Krebsmedikamente spezialisierten Arzneimittelgroßhändler Megapharm. Damit greift Alliance Boots die Hauptkonkurrenten im europäischen Pharmahandel, Celesio und Phoenix, in ihrem Heimatmarkt an. Experten hatten schon lange einen Einstieg der Briten in Deutschland erwartet. Alliance Boots betreibt neben dem Großhandel europaweit rund 1200 Apotheken. Im Falle einer Liberalisierung gilt es als sicher, dass die Briten, die 2007 etwa 19 Mrd. Euro umsetzten, auch in den deutschen Apothekenmarkt einsteigen. FTD
Dokument FTD0000020081016e4ag00031 |
